Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

More documents

Recommendations

Info

INDEX pharmacokinetics 518 in pruritis 267 Cyromazine 222, 225 Cytochrome P450/CYP enzymes 16, 32, 51, 52, 53 Cytokines gene therapy 285 modulation 399 recombinant 282–284 Cytosine arabinoside 336, 358–359 Cytotoxic drugs see cancer chemotherapy D D-MAC chemotherapy 366 Dacarbazine see DTIC chemotherapy Danazol 275–276 Danofloxacin 181–183 Dantrolene 88 Decoquinate 201, 238, 242–243 Deet 231–232 Dehydration corneal dehydrating agents 572 and prerenal azotemia 389 Delayed (Type D) adverse drug reactions (ADRs) 41 Deltamethrin 221, 236 Demecarium 570 Deoxycortisosterone pivalate (DOCP) 526–527 Dependence, opioid analgesics 315 Depolarizing muscle relaxants 67, 77–78 adverse effects 77 clinical applications 77 drug interactions 78 formulations and dose rates 77 mechanism of action 77 pharmacokinetics 77 ‘Depot’ injections 30 Deracoxib 298 Desflurane 85, 89, 92–93 Desipramine 136–138 Deslorelin 530 Detomidine 120–124 Dexamethasone (dexametasone) clinical applications 527, 541 drug interactions 287 ocular therapy 560, 561, 564 structure 525 topical 263 Dexamfetamine 133–134 Dexrazoxane 350 Dextromethorphan 464 Di-N-propylisocinchomeronate (MGK 326) 232 Diabetes mellitus 509–515 Diagnostic difficulties, adverse drug reactions (ADRs) 43–44 Diamino pyrimidine 239 Diazepam adverse effects 119, 135, 136 appetite stimulation 490, 491 behavior-modification 135 dosages 135, 368, 374 pharmacokinetics 118–119, 135 premedication 315 special considerations 119–120 in status epilepticus 368, 374 teratogenic effects 119 Diazinon 45, 221, 222 Dichlorophen 201, 206, 215 Dichlorphenamide 571 Dichlorvos 206, 220, 222 Diclofenac 558 Dicloxacillin 162 Diethylcarbamazine citrate (DEC) 206, 219–220 Diethylstilbestrol (DES) 540–541 Difloxacin 181–183 Digitalis glycosides 9, 53, 445–451 adverse effects 449–451 clinical applications 395–396, 445–446 dosing strategy 448 factors that alter dosage 447–448 formulations and dose rates 447 mechanism of action 446–447 pharmacokinetics 448–449 Digitalis toxicity 449–450 treatment 450–451 Digoxin 49, 384, 386, 422, 427 therapeutic drug monitoring (TDM) 37 Dihydrocodeine tartrate 465 Dihydrotachysterol 507–508 Diltiazem 384 cardiac arrhythmias 427, 444–445 ventricular relaxation 422–423 Dimenhydrinate 476–477 Diminazene 45, 199, 237, 243, 251 Dinoprost tromethamine 542–543 Diphenhydramine 129–130 antiemesis 476–477 in systemic anaphylaxis 267 Diphenoxylate 487–488 Dips, antiparasitic drugs 222, 223 Dipyrone 298–299 adverse effects 47, 299 clinical applications 298 drug interactions 299 formulations and dose rates 298 and hyoscine 483 pharmacokinetics 298 Discospondylitis, antibacterial drug choice 153 Disease and pharmacokinetics 18, 36–37, 50–52 Disophenol 201 Disopyramide 432 Disposal of medicines drug labeling 23 prescribing principles 26 Dissociative anesthetics 96–97 Distribution dogs vs cats 47 physiological basis 31–32 Diuretics 388–395 adverse effects 55, 389–390 caution/avoidance in renal and hepatic disease 53 clinical applications 388 in glaucoma 571 loop 390–393 mechanism of action 388–389 potassium-sparing 394–395 thiazide 393–394 Dobutamine 80 in heart failure 384, 396–397 Docusate sodium 485 Dog Appeasement Pheromone 144–145 Dolasetron 475 Domperidone 473–474 Dopamine 62, 69, 72 agonists 533–535 antagonists 535 and behavior 127–128 cardiovascular applications 397 sedative action 114 Dopamine receptors 8, 74 GIT 471 Doramectin 199, 210, 213, 245, 251, 253, 257 Dorzolamide 571 Dosage choice 35 drug effects 11–19 form 12–13 individualized regimens 34–36 see also species differences Dose–response curve 5, 6 Dose–response effect 46 Dosing frequency (T) 35–36, 39–40 Doxepin 129, 136, 136–138, 137 Doxorubicin 336, 348–351 adverse effects 49, 52, 333, 350–351 clinical applications 348, 349 drug interactions 351 formulations and dose rates 348–349 mechanism of action 348 mechanism of resistance 348 pharmacokinetics 349–350 Doxycycline 9 antiprotozoal dosage 240 ocular therapy 564, 566, 568 toxicity 152 Dozolamide 571 Droperidol 116–117 Drug action 3–4 Drug choice 35 antibacterials 152, 153 Drug classification 10 Drug concentration 33–34, 35–36, 37, 38–40 analyses 27 gradient 28–29 ‘steady-state’ 36, 39–40 Drug and dosage form 12–13 Drug interactions 16–17, 54 classification 54 mechanisms 17 see also named drugs/drug classes Drug labeling 22–23 and drug knowledge 25 extra-label uses 26, 45, 68 Drug nomenclature 8–10 Drug receptor binding 4–6 579
INDEX Drug receptors 4–8 Drug–drug hypersensitivity 55 Drug–receptor interaction 5–6 effect 6–7 Drug-induced antibody production 150 Drugs compendia 11 Dry eye therapy 570, 572–573 DTIC chemotherapy 336, 363 E Ear see Topical ear medications eCG (PMSG) 531, 532 Echinocandins 196 Econazole 189 Edrophonium chloride 78 EDTA 506 Efficacy studies, new chemical entities (NCEs) 21 Eflornithine 202 Eicosanoid fatty acids 541–543 Electrolyte abnormalities digitalis 450 diuretics 389 Elimination half-life 2–3, 34, 38–39 Emetic agents 496–497 Emodepside 204, 206, 214 Emollients 553 laxative 485 Emulsions 554 Enalapril 381, 412, 413–414, 416–417 adverse effects 416 formulations and dose rates 384, 386, 403, 416 pharmacokinetics 416–417 End of treatment (Type E) adverse drug reactions (ADRs) 42 Endectocides (avermectin-milbemycin class) 210–211 Endothelin receptor antagonists 424 Enrofloxacin 46, 49, 181–183 antiprotozoal uses 240 ocular therapy 564 Enteric nervous system (ENS) 60 Enteric-coated tablets 16 Enterohepatic circulation 30, 33, 50 antibacterial drug recycling 149, 174 atovaquone recycling 238` diazepam recycling 119 fipronil sulfone recycling 229 leflunomide metabolite recycling 278 methotrexate recycling 361 NSAID recycling 292, 295 Ursodeoxycholic acid recycling 491 warfarin recycling 456 Environmental issues antibacterials 150–151 drug labeling 23 inhalational anesthesia 89 new chemical entities (NCEs) 21 shampoos 548–549 580 Enzyme induction 17, 32–33, 51 Enzyme inhibition 4, 17, 33, 51 Ephedrine 80–81, 143 Epidural 110 morphine effects 321 Epinephrine (adrenaline) 61, 69, 72, 78–79 adverse effects 79 clinical applications 78–79 contraindications and precautions 79 convertion of noradrenaline to 128 drug interactions 79, 79, 110, 111, 116 formulations and dose rates 79 pharmacokinetics 79 Epirubicin 352 Epsiprantel 203, 206, 217 Ergocalciferol 507 Ergot alkaloids 74 behavior modification 145–146 Ergotamine 74 Errors, medical and medication 14–15 Erythromycin 484–485 adverse effects 152, 484 clinical applications 178 drug interactions 484–485 formulations and dose rates 484 mechanism of action 484 ocular therapy 565 pharmacokinetics 484 prokinetic action 484–485 Esmolol 419, 427, 437 Esophageal parasites 245 Estradiol and derivatives 540–541 Estrogen receptor 9 Estrogens 540–541 Estrus cycle 528–529 Estrus induction 529, 530, 531–532, 534 Estrus postponement/suppression 536, 539 Ethanol 51 Ethanolamine derivatives 266 Ethylenediamine derivatives 266 Ethyl lactate 552 Etodolac 299 Etomidate 96, 103–104 Etoposide 9, 333, 336, 338–339 European Agency for the Evaluation of Medicinal Products (EMEA) 46–47 Excipients 13 Excretion, physiological basis of 33 Exocrine pancreatic enzyme replacements 516 Exocrine pancreatic insufficiency 515–516 Expectorants 467 Extra-label uses 26, 45, 68 Extradural administration of opioids 316–317 Eye parasites 257–258 see also Topical ophthalmic therapy F Facilitated diffusion 29 Failure of treatment (Type F) adverse drug reactions (ADRs) 42, 43 Famotidine 478, 479 Helicobacter species eradication 483 Fat anesthetic agent solubility 89, 91, 92, 93, 98 body composition and dose calculation 48–49 blood flow 32 body fat and pharmacokinetic effects 19 drug accumulation 31, 32, 48, 214, 232 high-fat meal and pharmacokinetic effects 15, 16 atovaquone 238, 242 benzimidazoles 205, 208 ciclosporin 274 griseofulvin 194 voriconazole 191 Febantel 204, 206, 207, 208 adverse effects 48, 208 antiprotozoal action 238 Felbamate 368, 377–378 Feline cardiomyopathies 383, 386, 388 Feline infectious anemia 153 Feliway 144–145 Female reproductive physiology 528–529 Fenbendazole 204, 206, 208 antiprotozoal action 238 Fenoxycarb 225 Fentanyl 319, 323–324 patches 317–318 Fenthion 201, 222 Fever antibacterials, adjunctive treatments 156 drug metabolism in 19, 52 nonimmunologically mediated 56 NSAIDs 288 Fick’s law of diffusion 28 Finasteride 539–540 Fipronil 203, 222, 228–229 Firocoxib 287, 299–300 First aid drug labeling 23 prescribing principles 26 First-order process 34 First-pass effect 2, 30, 50–51 Florfenicol 156, 176 Fluanisone 116–117 Flubendazole 206, 207 Flucazole 567 Flucloxacillin 162 Fluconazole 189, 192 adverse effects 191 pharmacokinetics 190 Flucytosine 189 ocular therapy 567 9α-fludrocortisone 526
Page 1 and 2:
An imprint of Elsevier Limited © E
Page 3 and 4:
CONTRIBUTORS Matthias J Kleinz Depa
Page 5 and 6:
Dedication To Tom, Rosalind and Jim
Page 7 and 8:
CHAPTER 1 PRINCIPLES OF CLINICAL PH
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
CHAPTER 2 CLINICAL PHARMACOKINETICS
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
CHAPTER 3 ADVERSE DRUG REACTIONS Un
Page 49 and 50:
CHAPTER 3 ADVERSE DRUG REACTIONS to
Page 51 and 52:
CHAPTER 3 ADVERSE DRUG REACTIONS
Page 53 and 54:
CHAPTER 3 ADVERSE DRUG REACTIONS He
Page 55 and 56:
CHAPTER 3 ADVERSE DRUG REACTIONS an
Page 57 and 58:
CHAPTER 3 ADVERSE DRUG REACTIONS wh
Page 59 and 60:
CHAPTER 3 ADVERSE DRUG REACTIONS at
Page 61 and 62:
CHAPTER 3 ADVERSE DRUG REACTIONS Ps
Page 63 and 64:
CHAPTER 3 ADVERSE DRUG REACTIONS su
Page 65 and 66:
CHAPTER 4 THE PHARMACOLOGY OF THE A
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
CHAPTER 5 ANESTHETIC AGENTS However
Page 91 and 92:
CHAPTER 5 ANESTHETIC AGENTS The gre
Page 93 and 94:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 95 and 96:
CHAPTER 5 ANESTHETIC AGENTS doses.
Page 97 and 98:
CHAPTER 5 ANESTHETIC AGENTS ● hig
Page 99 and 100:
CHAPTER 5 ANESTHETIC AGENTS concent
Page 101 and 102:
CHAPTER 5 ANESTHETIC AGENTS X R 3 C
Page 103 and 104:
CHAPTER 5 ANESTHETIC AGENTS Emergen
Page 105 and 106:
CHAPTER 5 ANESTHETIC AGENTS inhalat
Page 107 and 108:
CHAPTER 5 ANESTHETIC AGENTS and enh
Page 109 and 110:
CHAPTER 5 ANESTHETIC AGENTS ● Exc
Page 111 and 112:
CHAPTER 5 ANESTHETIC AGENTS Pharmac
Page 113 and 114:
CHAPTER 5 ANESTHETIC AGENTS Central
Page 115 and 116:
CHAPTER 5 ANESTHETIC AGENTS Table 5
Page 117 and 118:
CHAPTER 5 ANESTHETIC AGENTS FURTHER
Page 119 and 120:
CHAPTER 6 SEDATIVES ● noradrenali
Page 121 and 122:
CHAPTER 6 SEDATIVES treatment, with
Page 123 and 124:
CHAPTER 6 SEDATIVES Benzodiazepines
Page 125 and 126:
CHAPTER 6 SEDATIVES It is not misci
Page 127 and 128:
CHAPTER 6 SEDATIVES respectively. H
Page 129 and 130:
CHAPTER 6 SEDATIVES Table 6.1 Sugge
Page 131 and 132:
7 Behavior-modifying drugs Kersti S
Page 133 and 134:
CHAPTER 7 BEHAVIOR-MODIFYING DRUGS
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
8 Antibacterial drugs Jill E Maddis
Page 155 and 156:
CHAPTER 8 ANTIBACTERIAL DRUGS phary
Page 157 and 158:
CHAPTER 8 ANTIBACTERIAL DRUGS dose
Page 159 and 160:
CHAPTER 8 ANTIBACTERIAL DRUGS Table
Page 161 and 162:
Page 163 and 164:
CHAPTER 8 ANTIBACTERIAL DRUGS Bacte
Page 165 and 166:
CHAPTER 8 ANTIBACTERIAL DRUGS lacta
Page 167 and 168:
CHAPTER 8 ANTIBACTERIAL DRUGS Antis
Page 169 and 170:
CHAPTER 8 ANTIBACTERIAL DRUGS intri
Page 171 and 172:
Page 173 and 174:
CHAPTER 8 ANTIBACTERIAL DRUGS inter
Page 175 and 176:
CHAPTER 8 ANTIBACTERIAL DRUGS Teico
Page 177 and 178:
CHAPTER 8 ANTIBACTERIAL DRUGS less
Page 179 and 180:
CHAPTER 8 ANTIBACTERIAL DRUGS Diffe
Page 181 and 182:
CHAPTER 8 ANTIBACTERIAL DRUGS forms
Page 183 and 184:
CHAPTER 8 ANTIBACTERIAL DRUGS ● I
Page 185 and 186:
CHAPTER 8 ANTIBACTERIAL DRUGS In an
Page 187 and 188:
CHAPTER 8 ANTIBACTERIAL DRUGS ● R
Page 189 and 190:
CHAPTER 8 ANTIBACTERIAL DRUGS RIFAM
Page 191 and 192:
9 Systemic antifungal therapy Josep
Page 193 and 194:
CHAPTER 9 SYSTEMIC ANTIFUNGAL THERA
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
10 Antiparasitic drugs Stephen W Pa
Page 205 and 206:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 207 and 208:
CHAPTER 10 ANTIPARASITIC DRUGS Tabl
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
CHAPTER 10 ANTIPARASITIC DRUGS leva
Page 217 and 218:
CHAPTER 10 ANTIPARASITIC DRUGS ●
Page 219 and 220:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 221 and 222:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 223 and 224:
CHAPTER 10 ANTIPARASITIC DRUGS Form
Page 225 and 226:
CHAPTER 10 ANTIPARASITIC DRUGS Mech
Page 227 and 228:
Page 229 and 230:
CHAPTER 10 ANTIPARASITIC DRUGS prod
Page 231 and 232:
CHAPTER 10 ANTIPARASITIC DRUGS Lufe
Page 233 and 234:
CHAPTER 10 ANTIPARASITIC DRUGS Adve
Page 235 and 236:
CHAPTER 10 ANTIPARASITIC DRUGS 62.5
Page 237 and 238:
CHAPTER 10 ANTIPARASITIC DRUGS incr
Page 239 and 240:
CHAPTER 10 ANTIPARASITIC DRUGS rest
Page 241 and 242:
CHAPTER 10 ANTIPARASITIC DRUGS The
Page 243 and 244:
CHAPTER 10 ANTIPARASITIC DRUGS 238
Page 245 and 246:
Page 247 and 248:
CHAPTER 10 ANTIPARASITIC DRUGS In a
Page 249 and 250:
CHAPTER 10 ANTIPARASITIC DRUGS func
Page 251 and 252:
CHAPTER 10 ANTIPARASITIC DRUGS Para
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
CHAPTER 11 GLUCOCORTICOSTEROIDS AND
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
12 Immunomodulatory therapy Michael
Page 277 and 278:
CHAPTER 12 IMMUNOMODULATORY THERAPY
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
CHAPTER 13 NONSTEROIDAL ANTI-INFLAM
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
CHAPTER 14 OPIOID ANALGESICS inflam
Page 317 and 318:
A Agonist opioid (morphine) B Parti
Page 319 and 320:
CHAPTER 14 OPIOID ANALGESICS admini
Page 321 and 322:
CHAPTER 14 OPIOID ANALGESICS may ac
Page 323 and 324:
CHAPTER 14 OPIOID ANALGESICS Small
Page 325 and 326:
CHAPTER 14 OPIOID ANALGESICS Clinic
Page 327 and 328:
CHAPTER 14 OPIOID ANALGESICS Contra
Page 329 and 330:
CHAPTER 14 OPIOID ANALGESICS respon
Page 331 and 332:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 333 and 334:
CHAPTER 14 OPIOID ANALGESICS Advers
Page 335 and 336:
15 Cancer chemotherapy Jane M Dobso
Page 337 and 338:
CHAPTER 15 CANCER CHEMOTHERAPY to m
Page 339 and 340:
CHAPTER 15 CANCER CHEMOTHERAPY curr
Page 341 and 342:
CHAPTER 15 CANCER CHEMOTHERAPY Tabl
Page 343 and 344:
CHAPTER 15 CANCER CHEMOTHERAPY Clin
Page 345 and 346:
CHAPTER 15 CANCER CHEMOTHERAPY sion
Page 347 and 348:
CHAPTER 15 CANCER CHEMOTHERAPY In t
Page 349 and 350:
CHAPTER 15 CANCER CHEMOTHERAPY afte
Page 351 and 352:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 353 and 354:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 355 and 356:
CHAPTER 15 CANCER CHEMOTHERAPY conc
Page 357 and 358:
CHAPTER 15 CANCER CHEMOTHERAPY ●
Page 359 and 360:
CHAPTER 15 CANCER CHEMOTHERAPY Phar
Page 361 and 362:
CHAPTER 15 CANCER CHEMOTHERAPY in t
Page 363 and 364:
CHAPTER 15 CANCER CHEMOTHERAPY Adve
Page 365 and 366:
CHAPTER 15 CANCER CHEMOTHERAPY best
Page 367 and 368:
CHAPTER 15 CANCER CHEMOTHERAPY Form
Page 369 and 370:
CHAPTER 15 CANCER CHEMOTHERAPY baso
Page 371 and 372:
CHAPTER 15 CANCER CHEMOTHERAPY D-MA
Page 373 and 374:
CHAPTER 16 ANTICONVULSANT DRUGS sei
Page 375 and 376:
CHAPTER 16 ANTICONVULSANT DRUGS bit
Page 377 and 378:
CHAPTER 16 ANTICONVULSANT DRUGS Kno
Page 379 and 380:
CHAPTER 16 ANTICONVULSANT DRUGS Mec
Page 381 and 382:
CHAPTER 16 ANTICONVULSANT DRUGS rap
Page 383 and 384:
CHAPTER 16 ANTICONVULSANT DRUGS exc
Page 385 and 386:
17 Drugs used in the management of
Page 387 and 388:
CHAPTER 17 DRUGS USED IN THE MANAGE
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
CHAPTER 19 GASTROINTESTINAL DRUGS C
Page 477 and 478:
CHAPTER 19 GASTROINTESTINAL DRUGS r
Page 479 and 480:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 481 and 482:
CHAPTER 19 GASTROINTESTINAL DRUGS c
Page 483 and 484:
CHAPTER 19 GASTROINTESTINAL DRUGS w
Page 485 and 486:
Page 487 and 488:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 489 and 490:
CHAPTER 19 GASTROINTESTINAL DRUGS i
Page 491 and 492:
CHAPTER 19 GASTROINTESTINAL DRUGS L
Page 493 and 494:
CHAPTER 19 GASTROINTESTINAL DRUGS P
Page 495 and 496:
CHAPTER 19 GASTROINTESTINAL DRUGS F
Page 497 and 498:
Page 499 and 500:
CHAPTER 19 GASTROINTESTINAL DRUGS Z
Page 501 and 502:
CHAPTER 19 GASTROINTESTINAL DRUGS
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
CHAPTER 21 DRUGS USED IN THE TREATM
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534: 23 Drugs and reproduction Philip G
Page 535 and 536: CHAPTER 23 DRUGS AND REPRODUCTION I
Page 537 and 538: CHAPTER 23 DRUGS AND REPRODUCTION F
Page 539 and 540: CHAPTER 23 DRUGS AND REPRODUCTION C
Page 541 and 542: CHAPTER 23 DRUGS AND REPRODUCTION M
Page 545 and 546: CHAPTER 23 DRUGS AND REPRODUCTION n
Page 547 and 548: CHAPTER 23 DRUGS AND REPRODUCTION E
Page 551 and 552: 24 Topical dermatological therapy R
Page 553 and 554: CHAPTER 24 TOPICAL DERMATOLOGICAL T
Page 563 and 564: CHAPTER 25 OCULAR CLINICAL PHARMACO
Page 579 and 580: Index A α-adrenergic receptors 70,
Page 581 and 582: INDEX Antiplatelet drugs 456-457 pi
Page 583: INDEX Ceftazidime 168 Ceftiofur 166
Page 587 and 588: INDEX Hepatic excretion 33 Hepatic
Page 589 and 590: INDEX Metabolism dogs vs cats 47 an
Page 591 and 592: INDEX Pentazocine 319, 327 Pentobar
Page 593 and 594: INDEX Semicarbazone 230 Septic arth
show all

Small Animal Clinical Pharmacology - CYF MEDICAL DISTRIBUTION

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?